BCAX · Bicara Therapeutics Inc. · Metrics
$18.35
+0.88 (+5.04%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$1.22B
Shares
66.17M
Volume · Oct 20
488.5K
Avg daily vol (3M)
671.3K
BCAX metrics
57 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$17.47
Market cap
$1.22B
Price action
20 metricsPrice change (1W)
+0.8%
Price change (30D)
-20.6%
Price change (3M)
-35.7%
Price change (6M)
-25.6%
Price change (YTD)
+3.8%
Price change (1Y)
-4.3%
Trailing year
Price change (5Y)
—
52-week high
$30.40
52-week low
$13.93
Change from 52-week high
-42.5%
Change from 52-week low
+25.4%
Annualized volatility
54.2%
Annualized volatility (3M)
55.3%
Beta
0.9
RSI (14D)
36.8
Price vs SMA 50
-18.9%
Price vs SMA 200
-18.0%
Avg volume (3M)
668,206
Relative volume
1.3
Average dollar volume
$14.76M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
66.17M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.4
reciprocal yield 41.3%
FCF yield
-11.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$201.99M
Net income (TTM)
−$185.36M
Trailing 12 months
Diluted EPS (TTM)
$-3.09
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+24.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-39.5%
Return on assets
-36.2%
Debt / equity
—
Current ratio
11.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$135.25M
Quick ratio
11.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$497.26M
Latest balance sheet
Cash & equivalents
$96.60M
Total assets
$512.24M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$134.85M
Capital expenditures (TTM)
$400,000
R&D (TTM)
$112.00M
SG&A (TTM)
—
Stock compensation (TTM)
$22.16M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
175
13F filer change QoQ
+29
Institutional ownership
105.9%
Conviction holders (share of 13F filers)
5.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-3.1%
Holder tenure
6.2
Price vs estimated holder cost
+67.8%
Ownership (registered funds)
1 metricsIndex-fund ownership
10.6%
Short interest
3 metricsShort interest
16.2%
Latest settlement · 14.2 days to cover
Days to cover
14.2d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.55M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—